SpyGlass Pharma, Inc. SGP
—
27.07
(0.58)
(2.10%)
as of 25 Sep
- Market cap
- $924.8M
- P/E
- 0.0×
Follow SGP
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
25.06 | 38.00 | 12.67 | 18.11 |
+5 more quarters Free account |
Net Debt/EBITDA |
10.83 | 16.63 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 0.98 | — | 0.00 | |
Capex/Depreciation |
(5.65) | (2.13) | — | (1.11) | |
Interest Coverage |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(0.50) | 0.00 | — | 0.00 | |
Cash per Share |
7.00 | 0.01 | 0.00 | 0.00 | |
Shareholders Equity per Share |
6.95 | 0.01 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | — | |
Book value per Share |
6.95 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow |
(16.77) | (14.22) | — | (8.99) | |
Working Capital |
227.02 | 246.70 | 100.18 | 113.09 | |
Capital Expenditures |
(1.93) | (0.68) | — | (0.15) | |
Net Current Asset Value |
225.39 | 245.09 | (105.93) | (94.54) | |
| Other line items | |||||
Quick Ratio |
24.89 | 37.75 | 12.57 | 17.92 | |
Revenue per Share |
0.00 | 0.00 | — | — | |
Operating CF per Share |
(0.44) | 0.00 | — | 0.00 | |
Capex per Share |
(0.06) | 0.00 | — | 0.00 | |
Average Receivables |
0.40 | — | — | — | |
Average Payables |
2.40 | — | — | — | |
Average Assets |
121.72 | 129.19 | 57.93 | 63.51 | |
Average Common Equity |
99.69 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | — | — |
Columns are period end dates